Cervical Cancer
Conditions
Brief summary
A Feasibility Trial of PVX7 vaccine in advanced cervical cancer patients who have completed primary definitive therapy.
Detailed description
A Feasibility Trial of PVX7 in advanced cervical cancer patients who have completed primary definitive therapy. * Safety and immunogenicity study * Patients are randomized in a 1:1 ratio to two cohorts, up to 16 patients in each of intramuscular or skin inoculation vaccine injection, up to 32 patients total * Human Immunodeficiency Virus (HIV)-negative patients only * Treatment dose: Arm A: pBI-11 DNA (3 mg) twice via intramuscular (IM) injection, followed by one dose of TA-HPV (2.5x10\^5 pfu) via skin inoculation; Arm B: pBI-11 DNA (3 mg) twice, followed by one dose of TA-HPV (10\^7 pfu) via IM injection * Schedule for administration: PVX7 vaccination at weeks 1, 5, and 9 * Follow-up for 2 years per standard of care (SoC)
Interventions
DRUGPVX7
PVX7 Immunotherapy
Sponsors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female subjects age 18 years or older with diagnosis of advanced (stage IB1-IVA) HPV+ cervical cancer and have completed primary treatment (consisting of any of the following as per NCCN guideline standard of care: surgical resection, radiation, and/or platinum-based chemotherapy) within the past 12 months. Patients who are recommended to receive anto-PD-1 or anti-PD-L1 therapy after chemoradiation are eligible to enroll and can continue to receive such therapy while receiving study drug. * No history of or current evidence of residual disease or disease recurrence based on imaging and clinical assessments within 8 weeks of enrollment * HIV uninfected * Hepatitis B surface antigen negative * Anti-hepatitis C (HCV) antibody negative or negative HCV polymerase chain reaction (PCR) * Patients who are able and willing to comply with all study procedures and voluntarily sign an informed consent form * Adequate organ function as defined by the following parameters: * white blood cell count ≥ 3,000 cells/cu mm * lymphocyte number ≥ 500 cells/cu mm * absolute neutrophil count ≥ 1,000 cells/cu mm * platelets ≥ 90,000/cu mm * hemoglobin ≥ 9 g/dL * total bilirubin \<1.5 X upper limit of normal (ULN), \<3 x ULN if Gilbert's disease * Aspartate Transferase(AST) and Alanine Transaminase (ALT) \<3 X ULN * creatinine \< 1.5 X ULN or estimated creatinine clearance ≥ 60 ml/min per Modified Cockcroft-Gault Formula * Eastern Cooperative Oncology Group performance status of 0 or 1 * All clinically significant toxicities related to prior therapy should be less than or equal to Grade 1 at time of enrollment * Ability and willingness for one month post vaccination to follow vaccine inoculation site care and avoid close social contact with children under 1 year old or close social or domestic contact with a pregnant woman or individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with past or present eczema, or immunodeficiency states including HIV infection
Exclusion criteria
* Women of child-bearing potential (i.e., those who have had fertility-sparing procedures for the management of cervical cancer) will be excluded unless agreed to remain sexually abstinent or have a partner who is sterile (i.e. vasectomy), or use methods of contraception (e.g., oral contraception, barrier methods, spermicide, intrauterine device (IUD)), throughout the first 6 months of the study. * Because there is a risk for adverse events in nursing infants, breastfeeding must be discontinued if the mother is treated on study. * Diagnosed with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; patients diagnosed with acquired, hereditary, or congenital immunodeficiencies * Diagnosis with a medical condition that requires systemic treatment with immunosuppressive drugs such as cyclosporine, adrenocorticotropic hormone (ACTH), alkylating agents, antimetabolites, radiation, Tumor Necrosis Factor (TNF) inhibitors, or systemic corticosteroids, either chronically or within 30 days of first PVX7 vaccination. * Administration of any blood product within 30 days of signing informed consent. * Need for ongoing therapeutic anticoagulation during the study period due to concern for increased risk of bleeding. * Previous severe allergic reaction or hypersensitivity to a vaccine or any of its components * Participation in a study with an investigational compound or device within 30 days of signing informed consent * Known active central nervous system disease * Surgery within 30 days of first PVX7 vaccination, excluding minor procedures * Diagnosis with an uncontrolled intercurrent illness including, but not limited to, ongoing, or active infection, or psychiatric illness/social situations that would limit compliance with study requirements * Diagnosis with an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis) * History of myocarditis or pericarditis. * Known underlying heart disease (e.g., cardiomyopathy, congestive heart failure, symptomatic arrhythmia not controlled by medication, unstable angina, history of acute myocardial infarction or cerebrovascular accident within the past 6 months). * Patients and the patients close social, sexual, or domestic contacts may not have non-healed wounds or active exfoliative skin conditions such as: Eczema, Burns, Impetigo, Varicella-zoster virus infection, Herpes simplex virus infection, Severe acne, Severe diaper dermatitis with extensive areas of denuded skin, Psoriasis, Lichen planus, Darier disease (keratosis follicularis). * History or presence of atopic dermatitis * Inability or unwillingness to for one month post vaccination follow vaccine inoculation site care and avoid social contact with children under 1 year old or close social or domestic contact with a pregnant woman or individuals at high risk of serious adverse effects of vaccinia virus, for instance, those with past or present eczema, or immunodeficiency states including HIV infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of PVX7 as assessed by adverse events | 12 months | To assess the safety of PVX7 immunotherapy to patients with advanced cervical cancer who have completed primary therapy by evaluating Adverse Events (AEs). |
| Feasibility of PVX7 | 12 months | To assess the feasibility of PVX7 immunotherapy to patients with advanced cervical cancer who have completed primary therapy. Feasibility is measured by the ability of patients to receive all three doses of vaccine. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cellular Immune Response | 12 months | To evaluate the systemic Human Papillomavirus (HPV)16/18 E6/E7-specific cellular immune responses to PVX7 immunotherapy by measuring the number of interferon gamma+ Cluster of Differentiation (CD)8 Tcells/mL with overlapping peptides covering HPV16/18 E6/E7 protein |
| Immune Response | 12 months | To compare the route of administration associated with the greatest immune response in patients with advanced cervical cancer who have completed primary standard of care treatment |
| Presence of circulating HPV DNA | 12 months | Measure presence of circulating HPV DNA load in blood pre- and post-PVX7 immunotherapy |
Countries
United States
Contacts
CONTACTStephanie Gaillard, MD
CONTACTAmy Deery, RN
PRINCIPAL_INVESTIGATORStephanie Gaillard, MD
Johns Hopkins University
Outcome results
None listed